pre-IPO PHARMA

COMPANY OVERVIEW

Artizan Biosciences, Inc. is a biotechnology company at the frontier of microbiome precision medicine, targeting, and blocking microbial-driven dysregulation and inflammation in the gut that is at the root cause of many serious diseases. The company’s proprietary drug discovery engine identifies and characterizes microbial drivers of disease within precise patient subsets in high-value areas including gastrointestinal, metabolic, autoimmune, and neurodegenerative diseases. Using a novel small molecule approach, Artizan modulates intestinal imbalance by inhibiting specific, disease-associated microbial virulence factors in the intestinal tract. The company’s platform with its lead program nearing the clinic in inflammatory bowel disease is validated by strategic partnerships with Biohaven Pharmaceuticals, Brii Biosciences, and Crohn’s and Colitis Foundation. Founded with IgA-SEQ™ technology and preeminent immunobiology expertise from Yale University, Artizan is based in New Haven, CT.


LOCATION

  • New Haven, CT, USA

  • THERAPEUTIC AREAS

  • Autoimmune Disease
  • Gastrointestinal Disease
  • Immunology
  • Inflammatory Disease
  • Neurodegenerative Disease
  • Neurological Disorders
  • Oncology

  • WEBSITE

    https://artizanbiosciences.com/


    CAREER WEBSITE

    https://artizanbiosciences.com/careers/


    SOCIAL MEDIA


    INVESTORS

    biohaven-pharmaceuticals brii-biosciences connecticut-innovations elm-street-ventures hatteras-venture-partners osage-university-partners


    PRESS RELEASES


    Jul 21, 2022

    Artizan Biosciences Announces Multi-Year Research Collaboration with the University Medical Center Utrecht and Microviable Therapeutics SL


    Mar 29, 2022

    Artizan Biosciences Announces Issuance of New U.S. Patent to Cover Proprietary Discovery Platform


    Jan 18, 2022

    Artizan Biosciences Selects Lead Product Candidate for Inflammatory Bowel Disease Therapeutic Development Program


    Nov 18, 2021

    Artizan Biosciences and Biohaven Therapeutics Announce Therapeutic Development Program in Parkinson’s Disease


    Oct 19, 2021

    Artizan Biosciences Announces Appointment of Dr. Bridget Martell as President and Chief Executive Officer


    For More Press Releases


    Google Analytics Alternative